QBS-72S for newly diagnosed glioblastoma with unmethylated MGMT promoter
Official title: Phase 1b/2a Trial of QBS-72S for the Treatment of Newly Diagnosed Glioblastoma Multiforme in Patients with Unmethylated MGMT Promoters
Funded at Quadriga Biosciences, INC. · NIH-10918037 · Data updated 2026-11-12
A new drug called QBS-72S is being given to people with newly diagnosed glioblastoma whose tumors lack MGMT promoter methylation.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Quadriga Biosciences, INC. NIH-funded |
| Lab location | 1 site (Los Altos, UNITED STATES) |
| Project start | June 1, 2013 |
| Project end | August 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $1,307,447 |
| NIH project number | 5R44CA174129-06 |
| Project ID | NIH-10918037 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with a new diagnosis of glioblastoma whose tumor testing shows an unmethylated MGMT promoter and who meet the trial's health and eligibility requirements.
✕Less likely to help
People with methylated MGMT promoters, recurrent GBM, significant other medical problems, or those unable to tolerate experimental therapy are less likely to benefit from this trial.
What this research studies
If I join, doctors would give QBS-72S—an experimental chemotherapy designed to cross the blood–brain barrier and kill tumor cells even when standard temozolomide is resisted. The drug uses a nitrogen-mustard mechanism to create DNA crosslinks and is carried into the brain by the LAT-1 transporter, which helps it reach tumors while sparing much normal tissue in lab tests. This early-phase trial will focus on testing safety, finding appropriate dosing, and looking for early signals that the drug helps tumors shrink or slows their growth. Participation would likely involve regular clinic visits, scans, blood tests, and other monitoring over weeks to months.
Why it matters
Potential benefit: If successful, QBS-72S could provide an effective treatment option that improves survival for patients with GBM whose tumors are resistant to temozolomide.
How similar studies have gone: Some alkylating drugs that cross the blood–brain barrier have been used before, but QBS-72S's LAT-1–assisted delivery and MGMT-independent action are novel and mainly supported by preclinical data so far.
Where this research is happening
-
Quadriga Biosciences, INC.
Los Altos, United States Active
Researchers
- Principal investigator: Ringold, Gordon M — Quadriga Biosciences, INC.
- Study coordinator: Ringold, Gordon M
Related research
Other NIH-funded projects on the same topics.
-
Role of a brain tumor RNA in glioblastoma where a unique lncRNA may drive cancer cells
A small, focused NIH grant explores how a brain cancer–related RNA called LINC01896 might control the growth of glioblastoma stem cells and influence treatment resistance.
-
Sonodynamic therapy for recurrent glioblastoma using MRI-guided focused ultrasound and ALA
A new treatment combines a drug called 5-ALA with MRI-guided focused ultrasound to target recurrent glioblastoma tumors.
-
Enhanced delivery of neural stem cells to brain cancer with a biodegradable gel and focused ultrasound
A new treatment approach uses patient-friendly neural stem cells delivered over several months with a biodegradable gel and ultrasound to target glioblastoma.
-
STAG2 mutations and 3D genome organization in glioblastoma
A study in adults with glioblastoma examines how STAG2 gene mutations may change the 3D structure of DNA in tumor cells and drive cancer.
-
Long-lasting stem-cell delivery for glioblastoma using an injectable gel and focused ultrasound
An injectable, biodegradable gel that slowly releases tumor‑killing neural stem cells, paired with focused ultrasound to allow non-surgical re-dosing, for people with glioblastoma.
-
Understanding the STAG2 Gene in Brain Tumors
This project aims to understand how changes in a specific gene called STAG2 contribute to the growth of glioblastoma, a common type of brain tumor.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.